A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With HNSCC (Master Protocol) (Pegathor Head and Neck 204)

PHASE2TerminatedINTERVENTIONAL
Enrollment

59

Participants

Timeline

Start Date

October 8, 2021

Primary Completion Date

July 21, 2023

Study Completion Date

November 26, 2024

Conditions
Squamous Cell Carcinoma of Head and Neck
Interventions
DRUG

Pembrolizumab

Pharmaceutical Form: Concentration for solution for infusion Route of Administration: Intravenous Infusion

DRUG

SAR444245 (Thor-707)

Pharmaceutical Form: Concentrate for solution for infusion Route of Administration: Intravenous Infusion

DRUG

Cetuximab

Pharmaceutical Form: Solution for infusion Route of Administration: Intravenous Infusion

Trial Locations (27)

704

Investigational Site Number : 1580003, Tainan City

1012

Investigational Site Number : 0320001, Buenos Aires

1066

Investigational Site Number : 5280002, Amsterdam

12200

Investigational Site Number : 2760004, Berlin

19107

Thomas Jefferson University Hospital Site Number : 8400003, Philadelphia

25123

Investigational Site Number : 3800003, Brescia

28040

Investigational Site Number : 7240005, Madrid

28046

Investigational Site Number : 7240003, Madrid

33075

Investigational Site Number : 2500003, Bordeaux

48109

University of Michigan- Site Number : 8400008, Ann Arbor

67033

Investigational Site Number : 2500002, Strasbourg

69008

Investigational Site Number : 2500008, Lyon

75015

Investigational Site Number : 2500006, Paris

80045

University of Colorado- Site Number : 8400004, Aurora

91010

City of Hope- Site Number : 8400007, Duarte

94800

Investigational Site Number : 2500001, Villejuif

98115

Seattle Cancer Care Alliance Site Number : 8400006, Seattle

2540488

Investigational Site Number : 1520004, Viña del Mar

4800827

Investigational Site Number : 1520002, Temuco

7500921

Investigational Site Number : 1520003, Santiago

8420383

Investigational Site Number : 1520001, Santiago

H4A 3J1

Investigational Site Number : 1240001, Montreal

6500 HB

Investigational Site Number : 5280001, Nijmegen

05505

Investigational Site Number : 4100002, Seoul

06351

Investigational Site Number : 4100001, Seoul

08035

Investigational Site Number : 7240001, Barcelona

08036

Investigational Site Number : 7240004, Barcelona

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Sanofi

INDUSTRY